While much of the focus remains on its impact on neurophysiological processes, there is growing curiosity about its broader implications across diverse biological systems. This article aims to explore ...
It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing’s disease.
Omass Therapeutics Ltd. has identified compounds acting as melanocortin MC2 receptor antagonists reported to be useful for the treatment of congenital adrenal hyperplasia, Cushing syndrome, depression ...